Organization (Industry)
GYRE THERAPEUTICS, INC.
ClinicalTrials.gov lists GYRE THERAPEUTICS, INC. as lead sponsor of 26 trials, counting the companies grouped under it. GYRE THERAPEUTICS, INC. itself has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers GYRE THERAPEUTICS, INC. and 1 company grouped under it: 26 lead-sponsored trials (0 its own, 26 in the grouped companies) and 1 legal-entity registration (1 its own, 0 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Beijing Continent Pharmaceutical Co, Ltd. | 26 | 0 |
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Major Depressive Disorder | 7 |
| Attention Deficit Disorder with Hyperactivity | 3 |
| Hemophilia B | 3 |
| Alzheimer Disease | 2 |
| Cognitive Dysfunction | 2 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 4 |
| 2019 | 2 |
| 2017 | 2 |
| 2014 | 1 |
| 2013 | 1 |
| 2011 | 6 |
| 2010 | 8 |
| 2009 | 2 |
| 2008 | 2 |
| 2007 | 1 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: none of the 24 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Mecamylamine | 1 |
| DONEPEZIL | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 29% hit target (n=7) | 57% on time (n=7) |
Journals published in (8)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Advances in therapy | 1 |
| Biological psychiatry | 1 |
| European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology | 1 |
| Journal of clinical pharmacology | 1 |
| Journal of clinical psychopharmacology | 1 |
Showing 5 of 8 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 117 | 4 | 2022-11-08 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 116,588,000 | 9,880,000 | 13,698,000 |
| 2024 | 105,757,000 | 17,898,000 | 12,024,000 |
| 2023 | 113,450,000 | -85,480,000 | 13,780,000 |
| 2022 | 102,290,000 | 4,314,000 | 16,686,000 |
| 2021 | 7,338,000 | -87,933,000 | 68,889,000 |
| 2020 | 20,948,000 | -56,241,000 | 52,975,000 |
| 2019 | not reported | -55,178,000 | 43,859,000 |
| 2018 | 6,000 | -30,055,000 | 21,474,000 |
| 2017 | 1,018,000 | -21,561,000 | 12,847,000 |
| 2016 | not reported | -16,945,000 | 11,555,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (38)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-06-10 | Other financing | not disclosed | Sec extracted |
| 2026-05-04 | Other financing | not disclosed | Sec extracted |
| 2026-03-02 | Other financing | not disclosed | Sec extracted |
| 2025-05-23 | Other financing | not disclosed | Edgar offerings |
| 2025-05-22 | Other financing | not disclosed | Edgar offerings |
Showing 5 of 38 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| ISU Abxis Co., Ltd. | Co sponsors trial with | 1 |
Latest dated events (186)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-06-10 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-05-04 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-02 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-05-23 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-05-22 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 186 events.
Biomarker capability evidence (45)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CD4 | Trial collaborator | Named in trial inclusion criteria |
| CFI | Trial sponsor | Named in trial inclusion criteria |
| CFI | Trial sponsor | Named in trial inclusion criteria |
| HAL | Trial sponsor | Named in trial inclusion criteria |
| INVS | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 45 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.